Clinical

• NanoViricides will begin a Phase II clinical trial next week for NV-387, an oral gummy drug designed to treat the Bundibugyo Ebola virus. • The trial responds to an expanding outbreak in the Democratic Republic of Congo where the crude fatality rate has reached 48%. • A successful treatment could reduce deaths and slow the spread of the virus during the largest outbreak currently affecting the region.

• Clinical trials for the oral drug NV-387 will begin to treat a rapidly expanding outbreak of the Bundibugyo Ebolavirus in the Democratic Republic of the Congo. • The virus has spread into displacement camps hosting over 4.4 million people who lack adequate drinking water, sanitation, and medical resources. • This trial is critical because there is currently no approved treatment or vaccine for this specific variant of the Ebolavirus Disease.

• NanoViricides will begin a clinical trial next week for the oral drug NV-387 to treat an expanding Ebola outbreak in the Democratic Republic of Congo. • The current outbreak of the Bundibugyo Ebolavirus variant has a 48% crude fatality rate and no approved treatment or vaccine. • The virus has spread into displacement camps hosting over 4.4 million people, creating a high-risk population with poor sanitation and medical resources.

• NanoViricides announced on September 8, 2026, that it has registered a Phase II clinical trial for NV-387 oral gummies to treat the Bundibugyo ebolavirus outbreak in the Democratic Republic of Congo. • The company reports that NV-387 previously performed better than the drug Remdesivir in a lethal animal model of a viral disease. • This trial addresses a critical gap in healthcare because there is currently no approved vaccine or treatment for the specific strain of ebolavirus causing the expanding outbreak.

• NanoViricides announced on September 8, 2026, that it registered a Phase II clinical trial for NV-387 oral gummies to treat the Bundibugyo Ebola virus. • The trial is listed in the Pan African Clinical Trials Database to address the expanding Ebola outbreak in the Democratic Republic of Congo. • This development provides a potential oral treatment option for patients in a region currently facing the largest Ebola outbreak on record.

• Government, industry, and public health sectors are collaborating to increase the adoption of common standards for clinical research data collection and sharing. • The initiative aims to prevent critical health findings from remaining hidden in fragmented data, ensuring that safety and efficacy results are transparent. • Current regulatory frameworks, including those from the U.S. FDA and the European Medicines Agency (EMA), typically require at least two well-controlled studies to validate a product's effectiveness.

• NanoViricides, Inc. (NYSE American: NNVC) announced on August 31, 2026, that it is preparing for clinical trials of its broad-spectrum drug candidate, NV-387. • The drug utilizes host-mimetic nanomedicine technology designed to treat measles, a disease currently seeing a rise in cases both within the USA and globally. • This development is significant as it aims to provide a revolutionary antiviral treatment that viruses cannot easily escape, addressing a critical gap in measles management.

Australian-led trial finds low risk of side effects from common cholesterol-lowering medication for otherwise healthy older peopleGet our breaking news email, free app or daily news podcastTaking a common cholesterol-lowering medication can reduce the risk of a heart attack or stroke for people aged over 70, with a low risk of serious side effects, a world-first clinical trial led by Australian researchers has found.Statins are already commonly prescribed to people under the age of 75 who meet certain risk criteria, such as having diabetes and high cholesterol, to prevent them from having a major heart event such as a heart attack, stroke, or from requiring heart surgery. Continue reading...

• Pulnovo Medical has enrolled the first two U.S. patients in its PULSE-LHD clinical trial at Henry Ford Hospital in Detroit. • The trial is conducted under an FDA Investigational Device Exemption (IDE) to evaluate pulmonary artery denervation for treating pulmonary hypertension associated with left heart disease. • This study is significant as it tests a novel medical device approach to managing complex heart failure and pulmonary hypertension conditions.

• Moderna and Merck have reported positive results from a large Phase 3 clinical trial of a personalized mRNA-based cancer vaccine designed to treat melanoma. • Unlike traditional treatments, this therapy trains a patient's own immune system to recognize and destroy the specific cancer cells threatening them. • This breakthrough represents a major step forward in precision oncology, moving away from broad attacks on cancer cells toward highly targeted immunotherapy.